An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Russia’s Gamaleya Centre says it will work on a product that could compete with semaglutide by using an oral probiotic that delivers GLP‑1, a hormone involved in appetite and blood sugar. In plain terms: a state research institute announced plans to make a pill-like probiotic that produces the same appetite‑reducing hormone that drugs like Ozempic and Wegovy mimic. GLP‑1 (glucagon‑like peptide‑1) is a natural chemical your gut releases after you eat. It sends signals that help you feel full, slows how fast your stomach empties, and helps control blood sugar. Semaglutide is a lab-made version that acts like GLP‑1 but lasts much longer in the body; it’s injected or comes as a specialized oral tablet. The idea behind a “probiotic GLP‑1” is to use live bacteria taken by mouth that are engineered to make GLP‑1 in the gut, rather than giving the hormone directly as a drug. The announcement is an intention to develop such a competitor, not a report of completed human trials. From the short news line we have, there’s no published study data, no details on how the probiotic would be engineered, and no evidence yet about effectiveness or safety in people. Historically, probiotic approaches that produce drugs inside the gut have been tested in animals and in very early human studies, but scaling those into reliable, regulated medicines is difficult. So at this stage it’s a development plan, not proof it works like semaglutide. Why this idea matters: if a safe, effective oral probiotic could reliably deliver GLP‑1 activity, it might offer an easier or cheaper alternative to injectable or specialty oral drugs. That could matter to people treating type 2 diabetes or people using GLP‑1 drugs for weight loss, since current treatments can be expensive and need prescription monitoring. A probiotic form might also change how the hormone acts, since producing it in the gut could have different timing or local effects. There are important caveats and risks. Engineering live bacteria to produce a hormone raises safety and regulatory challenges: ensuring the bacteria don’t spread, mutate, or produce too much hormone is crucial. Side effects seen with GLP‑1 drugs—nausea, stomach upset, and in rare cases more serious effects—could still occur, and we don’t know long‑term outcomes. The news item doesn’t say whether this would go through standard clinical trials or regulatory review. Until rigorous human trials are done and published, this remains a promising idea, not an approved treatment. Bottom line: Gamaleya announced plans to explore a probiotic that makes GLP‑1 as an alternative to semaglutide, but there’s no public evidence yet that it’s safe or effective in people.
Source: Новости GxP